[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634702":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":31,"responsibleParty":214,"collaborators":19,"id":216,"slug":19,"hasResults":217,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":19,"eligibilityCriteria":221,"healthyVolunteers":217,"sex":222,"minAge":223,"maxAge":19,"enrollmentInfo":224,"targetDuration":19,"studyType":227,"phases":228,"briefSummary":230,"conditions":231,"keywords":233,"overallStatus":34,"whyStopped":19,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":245},{"fullName":5,"class":6},"Novartis","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"QCZ484","EXPERIMENTAL","QCZ484 administered subcutaneously (SC) Q6M",[13],"Drug: QCZ484",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","QCZ484 subcutaneous injection, Q6M.",[9],null,[21],{"name":22,"affiliation":22,"role":23},"Novartis Pharmaceuticals","STUDY_DIRECTOR",[25,29],{"name":22,"role":26,"phone":27,"phoneExt":19,"email":28},"CONTACT","1-888-669-6682","novartis.email@novartis.com",{"name":22,"role":26,"phone":30,"phoneExt":19,"email":19},"+41613241111",[32,54,70,86,102,118,135,151,167,184,196,200,209],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"NICRs Research Center","RECRUITING","Garden Grove","California","92844","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-117.94145,33.77391,{"lat":44,"lon":43},[47,51],{"name":48,"role":26,"phone":49,"phoneExt":19,"email":50},"Maria Murillo","+1 909 206 2454","mmurillo@nicresearch.com",{"name":52,"role":53,"phone":19,"phoneExt":19,"email":19},"Mallu Reddy","PRINCIPAL_INVESTIGATOR",{"facility":55,"status":34,"city":56,"state":36,"zip":57,"country":38,"countryCode":39,"cosmosGeoPoint":58,"geoPoint":62,"contacts":63},"Downtown L A Research Center Inc","Los Angeles","90017",{"type":41,"coordinates":59},[60,61],-118.24368,34.05223,{"lat":61,"lon":60},[64,68],{"name":65,"role":26,"phone":66,"phoneExt":19,"email":67},"Claudia Cisneros","+1 213 261 3680","ccisneros@dtlaresearch.com",{"name":69,"role":53,"phone":19,"phoneExt":19,"email":19},"Salil U Nadkarni",{"facility":71,"status":34,"city":72,"state":73,"zip":74,"country":38,"countryCode":39,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"Entrust Clinical Research","Miami","Florida","33176",{"type":41,"coordinates":76},[77,78],-80.19366,25.77427,{"lat":78,"lon":77},[81,84],{"name":82,"role":26,"phone":19,"phoneExt":19,"email":83},"Mariuchi Mayon","mmayon@entrustclinicalresearch.com",{"name":85,"role":53,"phone":19,"phoneExt":19,"email":19},"Adolfo Cueli",{"facility":87,"status":34,"city":88,"state":73,"zip":89,"country":38,"countryCode":39,"cosmosGeoPoint":90,"geoPoint":94,"contacts":95},"Inpatient Research Clinical LLC","Miami Lakes","33014",{"type":41,"coordinates":91},[92,93],-80.30866,25.90871,{"lat":93,"lon":92},[96,100],{"name":97,"role":26,"phone":98,"phoneExt":19,"email":99},"Ilianys Marino","+1 786 502 4303","imarino@inpatientresearch.com",{"name":101,"role":53,"phone":19,"phoneExt":19,"email":19},"Alexis Gutierrez",{"facility":103,"status":34,"city":104,"state":73,"zip":105,"country":38,"countryCode":39,"cosmosGeoPoint":106,"geoPoint":110,"contacts":111},"Cardiology Partners Clinical Research Institute","Wellington","33449",{"type":41,"coordinates":107},[108,109],-80.24144,26.65868,{"lat":109,"lon":108},[112,116],{"name":113,"role":26,"phone":114,"phoneExt":19,"email":115},"Hiromi Hauserman","+1 561 537 4778","hiromi.hauserman@cardiologypartnerspl.com",{"name":117,"role":53,"phone":19,"phoneExt":19,"email":19},"Neerav Suresh Shah",{"facility":119,"status":34,"city":120,"state":121,"zip":122,"country":38,"countryCode":39,"cosmosGeoPoint":123,"geoPoint":127,"contacts":128},"Javara Research","Fayetteville","Georgia","30214",{"type":41,"coordinates":124},[125,126],-84.45493,33.44873,{"lat":126,"lon":125},[129,133],{"name":130,"role":26,"phone":131,"phoneExt":19,"email":132},"Shemeka Williams","229 518 4947","swilliams@javararesearch.com",{"name":134,"role":53,"phone":19,"phoneExt":19,"email":19},"William Cooper",{"facility":136,"status":34,"city":137,"state":138,"zip":139,"country":38,"countryCode":39,"cosmosGeoPoint":140,"geoPoint":144,"contacts":145},"Anderson Medical Research","Ft. Washington","Maryland","20744",{"type":41,"coordinates":141},[142,143],-77.02303,38.70734,{"lat":143,"lon":142},[146,149],{"name":147,"role":26,"phone":19,"phoneExt":19,"email":148},"Ann-Marie Cobb","andersonmedicalresearch@gmail.com",{"name":150,"role":53,"phone":19,"phoneExt":19,"email":19},"Felton Anderson",{"facility":152,"status":34,"city":153,"state":154,"zip":155,"country":38,"countryCode":39,"cosmosGeoPoint":156,"geoPoint":160,"contacts":161},"Jefferson City Medical Group","Jefferson City","Missouri","65109",{"type":41,"coordinates":157},[158,159],-92.17352,38.5767,{"lat":159,"lon":158},[162,165],{"name":163,"role":26,"phone":19,"phoneExt":19,"email":164},"Suzin Cunningham","suzin.cunningham@avacare.com",{"name":166,"role":53,"phone":19,"phoneExt":19,"email":19},"George Carr",{"facility":168,"status":34,"city":169,"state":170,"zip":171,"country":38,"countryCode":39,"cosmosGeoPoint":172,"geoPoint":176,"contacts":177},"Monroe Biomedical Research","Monroe","North Carolina","28112",{"type":41,"coordinates":173},[174,175],-80.54951,34.98543,{"lat":175,"lon":174},[178,182],{"name":179,"role":26,"phone":180,"phoneExt":19,"email":181},"Maya Patterson","+1 704 283 7359","Maya.Patterson@monroeresearch.com",{"name":183,"role":53,"phone":19,"phoneExt":19,"email":19},"Awawu Igbinadolor",{"facility":185,"status":34,"city":186,"state":187,"zip":188,"country":189,"countryCode":190,"cosmosGeoPoint":191,"geoPoint":195,"contacts":19},"Novartis Investigative Site","Suita","Osaka","5650853","Japan","JP",{"type":41,"coordinates":192},[193,194],135.51567,34.76143,{"lat":194,"lon":193},{"facility":185,"status":34,"city":197,"state":198,"zip":199,"country":189,"countryCode":190,"cosmosGeoPoint":19,"geoPoint":19,"contacts":19},"Shinjuku Ku","Tokyo","160-0008",{"facility":185,"status":34,"city":201,"state":19,"zip":202,"country":201,"countryCode":203,"cosmosGeoPoint":204,"geoPoint":208,"contacts":19},"Singapore","119074","SG",{"type":41,"coordinates":205},[206,207],103.85007,1.28967,{"lat":207,"lon":206},{"facility":185,"status":34,"city":201,"state":19,"zip":210,"country":201,"countryCode":203,"cosmosGeoPoint":211,"geoPoint":213,"contacts":19},"529889",{"type":41,"coordinates":212},[206,207],{"lat":207,"lon":206},{"type":215,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100634702",false,"NCT07543120","An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.","A Multicenter Open-label Extension Study to Evaluate Long-term Safety and Efficacy of QCZ484 in Hypertensive Patients.","Inclusion Criteria:\n\n1. Signed informed consent must be obtained prior to participation in the study.\n2. Successful completion of treatment period on QCZ484 study medication in parent study.\n3. No significant safety issue that may place participant at safety risk as determined by the Investigator.\n\nExclusion Criteria:\n\nParticipants meeting any of the following criteria, may it be pre-existing or developed during the parent study, are not eligible for inclusion in this study:\n\n1. Evidence of hepatic disease that would put participant at risk by taking QCZ484 for long term as determined by the Investigator.\n2. Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia), high-grade atrioventricular (AV) block (e.g., Mobitz type II and third-degree AV block in absence of a pacemaker) developed during the parent study.\n3. Permanent or persistent atrial fibrillation developed during the parent study.\n4. Clinically significant valvular heart disease developed during the parent study.\n5. Acute myocardial infarction (AMI) or unstable angina, or any percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) developed during the parent study. Any history of ischemic or hemorrhagic stroke or transient ischemic attack any time prior to enrollment.\n\nOther protocol-defined inclusion\u002Fexclusion criteria may apply","ALL","18 Years",{"count":225,"type":226},323,"ESTIMATED","INTERVENTIONAL",[229],"PHASE2","The purpose of this extension study is to collect additional safety and efficacy on QCZ484 for hypertensive patients who successfully completed the parent study, CQCZ484A12201 or additional QCZ484 studies as specified in the respective parent study protocols.",[232],"Hypertension (HTN)",[234,235,9],"Hypertension","open-label extension study","2026-06-29",{"date":238,"type":239},"2026-07-01","ACTUAL",{"date":241,"type":239},"2026-05-07",{"date":243,"type":226},"2031-11-30",{"name":22,"class":6},13]